CTLA4 and dermatomyositis: Abatacept (CTLA-4-Ig): A 2025 phase-3 trial of weekly subcutaneous abatacept plus standard care in refractory IIM showed no significant overall benefit at 24 weeks versus placebo, with a possible signal in non-DM subtypes; safety was acceptable.